Losartan more effective than atenolol in hypertension with left ventricular hypertrophy

Journal of Family Practice

Volumn 51, Issue 7, 2002, Pages 599-

  Montgomery, Lynda ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO;

ADULT; AGED; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOMES RESEARCH; RISK ASSESSMENT; SHORT SURVEY; STATISTICAL ANALYSIS;

EID: 0036318041     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (2)

1. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
2. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the losartan heart failure survival study ELITE II